11/18/2026 | Press release | Distributed by Public on 11/18/2026 10:09
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
As previously disclosed in the Current Reports on Form 8-K filed on March 17, 2026 and April 3, 2026, Drugs Made in America Acquisition II Corp. (the "Company") and Tal Alpha Yezum Vekidum Asakim (2003) Ltd. (the "Investor") are parties to the Definitive Investment and Sponsor Transition Agreement dated March 23, 2026 and effective March 24, 2026 (the "Agreement"). Under the Agreement, the Investor committed $1,400,000 of convertible notes financing to the Company (the "Convertible Notes Financing"). The Investor previously funded $450,000 through an unsecured convertible note in the principal amount of $150,000 issued on March 11, 2026 (the "Bridge Note") and an Interim Convertible Note in the principal amount of $300,000 issued on March 30, 2026 (the "Second Note").
On November 6, 2026, the Investor funded a further $250,000 under the Convertible Notes Financing, and the Company has received those funds. Following this installment, $700,000 of the Convertible Notes Financing has been funded and $700,000 remains available under the Agreement.
It has been agreed between the Company and the Investor that the Bridge Note, the Second Note and the $250,000 installment will be consolidated into a single convertible promissory note in the principal amount of $700,000 (the "Consolidated Note"), which will replace the Bridge Note and the Second Note. The Consolidated Note will mature on June 30, 2027, unless earlier converted, extending the maturities of the Bridge Note and the Second Note, which would otherwise have fallen in December 2026. The Consolidated Note will have the same conversion features as the prior notes: upon completion of a business combination, it may, at the option of the Investor, be converted into shares of the combined entity at a conversion price equal to a 35% discount to the market price of such shares at the time of conversion. The Consolidated Note will represent a direct financial obligation of the Company.
Item 8.01. Other Events.
Preliminary Proposal
On October 29, 2026, the Company delivered to Alpha AI Biotech Group ("Alpha") a preliminary proposal regarding a potential business combination (the "Proposal"). Alpha acknowledged and accepted the Proposal in principle on October 30, 2026.
The Proposal contemplates a pre-money equity valuation of Alpha of $600 million, payable in 60,000,000 ordinary shares of the Company at $10.00 per share. Alpha shareholders could also receive up to 30,000,000 additional ordinary shares as earn-out consideration, in two equal tranches subject to share-price thresholds of $12.50 and $15.00 during the 24 months after closing.
The Proposal is subject to, among other things, satisfactory due diligence, audited financial statements, execution of definitive agreements, and required board, shareholder and regulatory approvals.
Limited Standstill
On November 3, 2026, the Company's Board of Directors approved the Proposal's limited 30-day standstill, which expires on or about December 3, 2026 unless extended or terminated earlier. The standstill restricts only the consummation of a competing transaction; it does not prevent either party from evaluating or negotiating alternatives. The Board's approval of the standstill does not constitute approval of any business combination.
|
2 |
Binding and Nonbinding Terms
The Proposal is a nonbinding expression of interest, except for its confidentiality provisions, the limited standstill and the funding acknowledgment described below.
Working Capital Financing; Relationship of Mr. Tal
In connection with the Proposal, the Investor acknowledged its continuing commitment under the Agreement, including the $250,000 installment funded on November 6, 2026 and described in Item 2.03 above. The Investor's funding commitment is not contingent on approval or closing of the proposed transaction with Alpha.
Alon Izidor Tal, the Chief Executive Officer of the Investor, is also a director of Alpha and acknowledged the Proposal on Alpha's behalf. The Agreement also contains provisions relating to a transition of the Company's sponsor, as described in the Current Report on Form 8-K filed on April 3, 2026. The Company's Board of Directors, which consists entirely of independent directors, was aware of Mr. Tal's relationships with both Alpha and the Investor when it approved the standstill.
No Assurance
No definitive business combination agreement has been executed. There can be no assurance that a definitive agreement will be executed, that the proposed terms will be maintained, that any earn-out shares will become issuable, or that any transaction will be consummated.